Wilbert Bannenberg, MD, MPH, Pharmaceutical systems expert

  • Pharmaceutical systems: National Medicines Policy development and implementation support, access to essential medicines, regulatory systems support, drug legislation, intellectual property rights issues and medicines, drug financing, quantification of essential drugs' needs, selection of essential drugs and formulary development, rational use of drugs, training, capacity building and networking.

  • Wilbert Bannenberg joined hera in 2002.

  • His experience is in Anglophone Africa (Ethiopia, Ghana, Kenya, Lesotho, Malawi, South Africa, Tanzania, Zimbabwe, Zambia), the Caribbean (Suriname) and Central Asia (Mongolia).

  • Apart from hera, Wilbert is the founder of E-DRUG, an internet community on essential medicines. He is also supporting NGO’s and teaching about access to medicines at various Universities. In 2018 he set up the Pharmaceutical Accountability Foundation, which aims to ensure access to excessively priced medicines using legal procedures and Human Rights principles.

Contact: Wilbert.Bannenberg@hera.eu

Related Stories

News
hera supports the government of Mongolia in improving access to affordable medicines
hera supports the government of Mongolia in improving access to affordable medicines

The Mongolian Vice Minister of Health, Byambsuren Lamjav, met with a hera team in October to discuss ongoing work on improving access to affordable medicines in public hospitals in Mongolia. hera is providing technical assistance to the new government under an Asian Development Bank cooperative project.

Final evaluation of the project Consolidating Cardiovascular Services at the national cardiac centre in Mongolia
Final evaluation of the project Consolidating Cardiovascular Services at the national cardiac centre in Mongolia

hera partner Michèle Kosremelli Asmar is part of the PROMAN consortium implementing the Third-Party Monitoring of the Lebanon Health Programme for Syrian Refugees and Vulnerable Lebanese Population funded by the European Union through the MADAD fund.

Mid-term review of the EU/ACP/WHO Renewed Partnership for strengthening pharmaceutical systems and improving access to quality medicines in 15 African ACP Countries
Mid-term review of the EU/ACP/WHO Renewed Partnership for strengthening pharmaceutical systems and improving access to quality medicines in 15 African ACP Countries

The “The Renewed EU/ACP/WHO Partnership” (RP) was a four year programme (October 2012 – September 2016) with the overall objective to contribute to the achievement of health-related MDGs and to universal health coverage in African ACP countries by improving the availability, affordability and use of safe, effective and quality assured essential medicines for the treatment of priority acute and non-communicable diseases.

SADC Feasibility Study on Regional Manufacturing of Medicines and Health Commodities
SADC Feasibility Study on Regional Manufacturing of Medicines and Health Commodities

Assess the feasibility of the local production of essential medicines especially those related to the three communicable diseases, namely HIV and AIDS, TB and Malaria as well as the production of health commodities for the three diseases.

Assessing the Impact: BMGF & DFID's Reproductive Health Programmes in Low- and Middle-Income Countries
Assessing the Impact: BMGF & DFID's Reproductive Health Programmes in Low- and Middle-Income Countries

In an effort to promote reproductive health and accessibility to quality-assured reproductive health commodities in low- and middle-income countries, the Bill & Melinda Gates Foundation (BMGF) and the Department for International Development (DFID), now known as the Foreign, Commonwealth & Development Office (FCDO), rolled out two independent, yet complementary, programmes geared towards ensuring hormonal contraceptives become more readily available, of high quality and affordable.